Investor Relations

Print   Email  
Stock price graph
     

Ocera is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's lead program, OCR-002, is an ammonia scavenger designed to treat hyperammonemia (elevated ammonia in the blood) and associated hepatic encephalopathy, a complication of patients with liver cirrhosis. In addition to OCR-002, Ocera has developed Zysa™ (AST-120), a spherical carbon adsorbent, for the treatment of irritable bowel syndrome.

View all »   RSSRecent Releases

Mar 13, 2014
Ocera Reports Fourth Quarter and Year-End 2013 Financial Results

Mar 4, 2014
Ocera Therapeutics to Announce Fourth Quarter and Year End Financial Results

Investors